Hospital, Canada; the 4Department of HaematologylOnocology, Tufts, Boston; and the 5Department of Molecular and Cell Biology, University of Sussex. SUMMARY The genetic background of systemic lupus erythematosus (SLE) has been reexamined in a study of the serum of 31 lupus patients and 80 asymptomatic first degree relatives by measuring a common, cross reacting anti-DNA antibody idiotype designated 134, antibodies to poly(ADP-ribose), serum C3, circulating immune complexes, and antinuclear antibodies (ANA). Over 30% of the relatives had raised 134 and anti-poly(ADP-ribose) levels, and 9% had ANA titres> 1/20. In contrast, only one relative had a low serum C3 level. These results confirm that immunogenetic abnormalities associated with the production of autoantibodies and particular idiotypes must exist amongst lupus relatives as well as the patients. The production of autoantibodies, however, is not necessarily matched to the clinical expression of SLE. 
We have also examined the sera for circulating immune complex levels, serum C3 levels, and the presence of antinuclear antibodies by immunofluorescence on a HEp2 cell line.
Patients and methods

PATIENTS
Thirty one patients with SLE from 30 different families were studied. Twenty nine of these patients were female, and all patients, male and female, fulfilled four or more of the American Rheumatism Association's revised criteria for the classification of SLE.20 Sera from 80 of their healthy first degree relatives, 49 female and 31 male, were also included in the study. The (SD 7 4) . The upper limit of normal was set at 32% (> mean +2SD). Only one of the controls (2o5%) exceeded this. In contrast. 18 of the lupus patients (58% ) and 35 (44%) of the relatives were found to have raised levels of anti-poly(ADP-ribose) antibodies (see Fig.  1 ). When the median group values were compared there were significant differences between both patient and relative groups and the normal population (p<0.01. Mann-Whitney U test). The difference between patient and relative groups did not reach significance.
Serum levels of the 134 idiotype in the 40 healthy controls gave a mean percentage value (compared with the value for the known high positive individual) of 10-5%/ ±10%. Fourteen of the 31 patients (45%) and 24 of the 80 relatives (30%) had 134 idiotype levels in excess of the upper limit of normal also set at 32% (>mean+2SD). Only one of the controls exceeded this value (Fig. 2) showed a statistically significant difference between both patient and relative groups and the normals (p<O-000l, Mann-Whitney U test), but no difference between the patient and relative groups. The relatives with high 134 idiotype levels were confined to 10 families. In six of these families the index case also had a raised 134 idiotype level. One family was notable as the index case and five relatives had high levels. In two other families the index case and three relatives had raised 134 idiotype levels. Of the 11 patients and 20 relatives with high 134 idiotype levels who were tested for anti-DNA antibodies, nine of the patients, but only five of the relatives, had raised levels of IgG/IgM antibodies to ss/dsDNA. The difference was statistically significant (p<0_01, x2 analysis).
Circulating immune complex levels were raised in 13 (46%) of the lupus patients but in only seven (10%) of the relatives (see Fig. 3 These studies used radioimmunoassays. In this study, using an ELISA, we have confirmed that healthy individuals do not express anti-poly(ADPribose) antibodies, though they are found in many SLE patients. More than 40% of healthy family members, however, also had raised levels.
In our previous report we examined idiotypes first identified on hybridoma derived monoclonal antissDNA antibodies and showed that these idiotypes
group Approaches similar to those employed in tracing the idiotype through the family could be used to trace the development of anti-poly(ADP-ribose) antibodies. This might give some clue as to the stimulus for their production. A vertical inheritance through one parent to one of many children, for example, would provide evidence against an infectious aetiology.
In this study very few patients or relatives had low C3 levels. This may reflect the fact that many of the patients, who were attending outpatient clinics, had restricted disease activity. In addition, the bias in our departments is towards patients with rheumatological or haematological disease, or both, rather than towards those with renal involvement, which is more commonly associated with low C3 levels.
Forty six per cent of the SLE patients had raised circulating immune complex (CIC) levels, but only 10% of relatives had values above the normal limit. This is in contrast with the work of Elkon et 
